ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,646 SEK | +0.27% |
|
+10.14% | +21.61% |
| Apr. 26 | ASTRAZENECA : DZ Bank sticks Neutral | ZD |
| Apr. 26 | ASTRAZENECA : UBS keeps a Sell rating | ZD |
| Sales 2024 * | 51.18B 560B | Sales 2025 * | 54.76B 599B | Capitalization | 231B 2,532B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.52B 93.2B | Net income 2025 * | 10.2B 112B | EV / Sales 2024 * | 4.91 x |
| Net Debt 2024 * | 19.9B 218B | Net Debt 2025 * | 13.44B 147B | EV / Sales 2025 * | 4.47 x |
| P/E ratio 2024 * |
27.2
x | P/E ratio 2025 * |
22.9
x | Employees | 89,900 |
| Yield 2024 * |
2.09% | Yield 2025 * |
2.18% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | +0.27% | ||
| 1 week | +10.14% | ||
| Current month | +13.32% | ||
| 1 month | +13.63% | ||
| 3 months | +17.24% | ||
| 6 months | +18.50% | ||
| Current year | +21.61% |
1 week
1 499.50
1 656.00
1 month
1 416.501 656.00
Current year
1 261.001 656.00
1 year
1 261.001 656.00
3 years
863.601 656.00
5 years
700.001 656.00
10 years
447.501 656.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1,646 | +0.27% | 316,442 |
| 24-04-25 | 1,642 | +6.35% | 917,143 |
| 24-04-24 | 1,544 | +1.41% | 341,079 |
| 24-04-23 | 1,522 | -0.49% | 243,301 |
| 24-04-22 | 1,530 | +2.34% | 306,741 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-28
- Roadshow - Day 1
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3
USD
Average target price
164.4
USD
Spread / Average Target
+10.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B | |
| -11.77% | 144B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
